Pfizer
1Q Revenues: $18.3 billion (-29%)
1Q Earnings: $5.5 billion (-30%)
Comments: Primary care revenues were down 37% to $11.5 billion in the quarter. Specialty care sales were up 8% to $3.6 billion. Oncology sales were down 1% to $2.9 billion. Revenues from Comirnaty and Paxlovid were $7.1 billion in the quarter. Comirnaty sales were $3.1 billion, down 77% and Paxlovid sales were $4.0 billion, up from $1.5 billion 1Q222. Recently acquired products, Nurtec ODT/Vydura and Oxbryta, contributed $167 million and $71 million in global revenues in the quarter, respectively. Sulperazon sales were up 52% to $320 million. Eliquis sales were up 5% to $1.9 billion. Prevnar family revenues were $1.6 billion, up 2%. Vyndaqel family sales were $686 million, up 12%. Xeljanz sales were down 36%, driven primarily by lower net price in the U.S. and decreased prescription volumes worldwide resulting from ongoing shifts in prescribing patterns related to label changes. Enbrel sales (Outside the U.S. and Canada) were down 29% to $199 million. Ibrance sales were down 8% to $1.1 billion. Pfizer CentreOne revenues were $306 million in the quarter, down 10%.